🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Global Access

As per results published in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The trial included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Having a single-dose, oral treatment such as this is described as a "critical tool" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea around the world.